MCID: TCL004
MIFTS: 47

T-Cell Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for T-Cell Leukemia

MalaCards integrated aliases for T-Cell Leukemia:

Name: T-Cell Leukemia 12 52 15 17
Leukemia, T-Cell 43 71
Leukemia, T-Cell, Chronic 52
Chronic T-Cell Leukemia 52
Leukemia T-Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:715
MeSH 43 D015458
UMLS 71 C0023492

Summaries for T-Cell Leukemia

MalaCards based summary : T-Cell Leukemia, also known as leukemia, t-cell, is related to acute t cell leukemia and human t-cell leukemia virus type 1. An important gene associated with T-Cell Leukemia is MIR106A (MicroRNA 106a), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human T-cell leukemia virus 1 infection. The drugs Zidovudine and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone.

Related Diseases for T-Cell Leukemia

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3

Diseases related to T-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 551)
# Related Disease Score Top Affiliating Genes
1 acute t cell leukemia 35.0 TLX3 TLX1 TCL6 TAL1 LMO1
2 human t-cell leukemia virus type 1 35.0 CRTC2 CREB1
3 leukemia 32.5 TLX3 TLX1 TCTA TCL6 TCL1B TCL1A
4 precursor t-cell acute lymphoblastic leukemia 32.2 TLX3 TLX1 TCL1A TAL1 LMO1
5 lymphoma 32.1 TLX1 TCL6 TCL1B TCL1A TAL1 IL2
6 adult t-cell leukemia 13.1
7 human t-cell leukemia virus type 2 12.8
8 pediatric t-cell leukemia 12.6
9 human t-cell leukemia virus type 3 12.6
10 n syndrome 12.0
11 t-cell adult acute lymphocytic leukemia 11.9
12 htlv-1 associated myelopathy/tropical spastic paraparesis 11.9
13 t-cell prolymphocytic leukemia 11.8
14 myelopathy, htlv-1-associated 11.8
15 tropical spastic paraparesis 11.8
16 t-cell childhood acute lymphocytic leukemia 11.5
17 glut1 deficiency syndrome 1 11.3
18 retrovirus-associated myelopathy 11.3
19 follicular lymphoma 11.2
20 agammaglobulinemia 11.1
21 hepatosplenic t-cell lymphoma 11.1
22 lymphocytic leukemia 11.0
23 spastic paraparesis 11.0
24 chronic interstitial cystitis 10.9
25 leukemia, acute lymphoblastic 10.8
26 alcoholic hepatitis 10.8
27 human immunodeficiency virus type 1 10.7
28 severe combined immunodeficiency 10.7
29 leukemia, chronic lymphocytic 10.7
30 mycosis fungoides 10.7
31 acquired immunodeficiency syndrome 10.7
32 cutaneous t cell lymphoma 10.6
33 gallbladder melanoma 10.6 SLC2A1 IL2
34 peripheral t-cell lymphoma 10.6
35 lymphoproliferative syndrome 10.6
36 graft-versus-host disease 10.6
37 b-cell lymphoma 10.6
38 uveitis 10.5
39 prolymphocytic leukemia 10.5
40 strongyloidiasis 10.5
41 hairy cell leukemia 10.5
42 splenomegaly 10.5
43 acute leukemia 10.5
44 exanthem 10.5
45 neutropenia 10.5
46 immunodeficiency 18 10.5 TAL1 LMO1
47 bone resorption disease 10.5
48 chromosomal triplication 10.5
49 lymphoma, hodgkin, classic 10.4
50 immune deficiency disease 10.4

Graphical network of the top 20 diseases related to T-Cell Leukemia:



Diseases related to T-Cell Leukemia

Symptoms & Phenotypes for T-Cell Leukemia

Drugs & Therapeutics for T-Cell Leukemia

Drugs for T-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 315)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4 Anti-Retroviral Agents Phase 4
5 Anti-HIV Agents Phase 4
6 Reverse Transcriptase Inhibitors Phase 4
7 Interferon-alpha Phase 4
8 Interferon alpha-2 Phase 4
9 interferons Phase 4
10 GABA Agents Phase 4
11 Antimanic Agents Phase 4
12 Anticonvulsants Phase 4
13
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
14
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
15
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
16
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
17
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
18
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
19 Orange Approved Phase 3
20
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
21
Dalteparin Approved Phase 3 9005-49-6
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
23
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
24
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 3 82419-36-1 4583
27
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
28
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
29
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
30
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
31
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
32
Piperacillin Approved Phase 3 66258-76-2 43672
33
Tazobactam Approved Phase 3 89786-04-9 123630
34
Vancomycin Approved Phase 3 1404-90-6 441141 14969
35
Daunorubicin Approved Phase 3 20830-81-3 30323
36
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
37
Pegaspargase Approved, Investigational Phase 3 130167-69-0
38
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
40
Mercaptopurine Approved Phase 3 50-44-2 667490
41
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
42
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
43
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
44
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
45
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
46
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
47 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
48 Amoxicillin-Potassium Clavulanate Combination Phase 3
49 Anesthetics, Dissociative Phase 3
50
asparaginase Phase 3

Interventional clinical trials:

(show top 50) (show all 371)
# Name Status NCT ID Phase Drugs
1 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
7 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
8 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
10 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
11 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
12 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
14 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
15 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
16 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
17 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
18 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
19 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
20 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
22 ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
23 Treatment of Acute Lymphoblastic Leukemia in Children Completed NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
24 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
25 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
26 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
27 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
28 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
29 A Phase III Study of Involved Field Radiation Therapy (IFRT) in Patients With Histologically Aggressive Non-Hodgkin's Lymphoma Following High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Completed NCT00031668 Phase 3
30 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
31 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Recruiting NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
32 A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia Recruiting NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
33 A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008. Active, not recruiting NCT00707083 Phase 3 dexamethasone;mercaptopurine;methotrexate;vincristine sulfate
34 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
35 Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
36 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Unknown status NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
37 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
38 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
39 DFCI ALL Adult Consortium Protocol: Adult ALL Trial Unknown status NCT01005758 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide phosphate;hydrocortisone sodium succinate;imatinib mesylate;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;prednisone;vincristine sulfate
40 MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) Unknown status NCT00002531 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;teniposide;thioguanine;vincristine sulfate;vindesine
41 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
42 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
43 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
44 Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia Unknown status NCT00003885 Phase 2 arsenic trioxide
45 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
46 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
47 Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Irritable Bowel Syndrome Unknown status NCT02423421 Phase 2
48 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
49 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2
50 A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)

Search NIH Clinical Center for T-Cell Leukemia

Cochrane evidence based reviews: leukemia, t-cell

Genetic Tests for T-Cell Leukemia

Anatomical Context for T-Cell Leukemia

MalaCards organs/tissues related to T-Cell Leukemia:

40
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Skin, Liver

Publications for T-Cell Leukemia

Articles related to T-Cell Leukemia:

(show top 50) (show all 8800)
# Title Authors PMID Year
1
Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. 61 46
19464056 2009
2
Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. 61 46
18974142 2008
3
Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. 61 46
17575136 2007
4
Transactivation of human osteopontin promoter by human T-cell leukemia virus type 1-encoded Tax protein. 54 61
19767100 2010
5
Cyclic AMP response element-binding protein is implicated in IL-6 production from arthritic synovial cells. 54 61
19921094 2010
6
Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia. 54 61
20154469 2010
7
Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation. 54 61
19836302 2009
8
Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1. 54 61
19587703 2009
9
Transcriptional activation of the interleukin-21 gene and its receptor gene by human T-cell leukemia virus type 1 Tax in human T-cells. 54 61
19617351 2009
10
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. 54 61
19561642 2009
11
Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. 54 61
19564891 2009
12
Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. 54 61
19555512 2009
13
The mechanism of chemokine receptor 9 internalization triggered by interleukin 2 and interleukin 4. 54 61
19567201 2009
14
Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. 54 61
19487290 2009
15
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. 54 61
19461887 2009
16
Double minute chromosomes containing MYB gene and NUP214-ABL1 fusion gene in T-cell leukemia detected by single nucleotide polymorphism DNA microarray and fluorescence in situ hybridization. 54 61
18799215 2009
17
Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway. 54 61
19200568 2009
18
HTLV-1 Tax is a critical lipid raft modulator that hijacks IkappaB kinases to the microdomains for persistent activation of NF-kappaB. 54 61
19129196 2009
19
Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. 54 61
19147787 2009
20
T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. 54 61
19155496 2009
21
Rev and Rex proteins of human complex retroviruses function with the MMTV Rem-responsive element. 54 61
19192308 2009
22
Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. 54 61
19352436 2009
23
Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. 54 61
18534198 2009
24
The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter. 54 61
18815299 2008
25
Ikaros regulates Notch target gene expression in developing thymocytes. 54 61
18941217 2008
26
(-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. 54 61
18687687 2008
27
Foxp3 expression on normal and leukemic CD4+CD25+ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. 54 61
18510697 2008
28
Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. 54 61
18678383 2008
29
An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ. 54 61
18599479 2008
30
Role of human T-cell leukemia virus type I Tax in expression of the human telomerase reverse transcriptase (hTERT) gene in human T-cells. 54 61
18422743 2008
31
In vitro activation of the IkappaB kinase complex by human T-cell leukemia virus type-1 Tax. 54 61
18223255 2008
32
Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation. 54 61
18287091 2008
33
The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. 54 61
18227842 2008
34
The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. 54 61
18246070 2008
35
Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells. 54 61
18287585 2008
36
The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB. 54 61
18070920 2008
37
Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells. 54 61
18178833 2008
38
Regulation of telomerase and telomeres: human tumor viruses take control. 54 61
18182620 2008
39
Evaluation and validation of housekeeping genes in response to ionizing radiation and chemical exposure for normalizing RNA expression in real-time PCR. 54 61
17904413 2008
40
Decontamination of leukemic cells and enrichment of germ cells from testicular samples from rats with Roser's T-cell leukemia by flow cytometric sorting. 54 61
18042634 2007
41
Activation of the human T-cell leukemia virus type 1 long terminal repeat by the ternary complex factor Elk-1. 54 61
17898074 2007
42
The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. 54 61
17846228 2007
43
Notch and Ikaros: not only converging players in T cell leukemia. 54 61
18032925 2007
44
Cooperation of NF-kappaB2/p100 activation and the PDZ domain binding motif signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is crucial for interleukin-2-independent growth transformation of a T-cell line. 54 61
17715223 2007
45
Targeting autophagic regulation of NFkappaB in HTLV-I transformed cells by geldanamycin: implications for therapeutic interventions. 54 61
17671417 2007
46
Neurotropin demonstrates cytoprotective effects in lung cells through the induction of thioredoxin-1. 54 61
17585112 2007
47
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. 54 61
17873882 2007
48
Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. 54 61
17540846 2007
49
BCL3 acts as a negative regulator of transcription from the human T-cell leukemia virus type 1 long terminal repeat through interactions with TORC3. 54 61
17644518 2007
50
Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. 54 61
17609265 2007

Variations for T-Cell Leukemia

Expression for T-Cell Leukemia

Search GEO for disease gene expression data for T-Cell Leukemia.

Pathways for T-Cell Leukemia

Pathways related to T-Cell Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 TCL1B TCL1A IL2 CRTC2 CREB1 ATF4
2 11.69 SLC2A1 IL2 CRTC2 CREB1 ATF4
3
Show member pathways
11.59 SLC2A1 CRTC2 CREB1
4 11.48 SLC2A1 CRTC2 CREB1 ATF4
5 11.23 SLC2A1 CREB1 ATF4
6 10.85 MIR92A2 MIR20B MIR19B2 MIR106A

GO Terms for T-Cell Leukemia

Cellular components related to T-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATF4-CREB1 transcription factor complex GO:1990589 8.62 CREB1 ATF4

Biological processes related to T-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.7 TLX1 TAL1 LMO1 IL2 CRTC2 CREB1
2 negative regulation of angiogenesis GO:0016525 9.5 MIR92A2 MIR20B MIR143
3 miRNA mediated inhibition of translation GO:0035278 9.43 MIR92A2 MIR19B2 MIR106A
4 negative regulation of cholesterol efflux GO:0090370 9.37 MIR19B2 MIR130B
5 gene silencing by miRNA GO:0035195 9.1 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A
6 regulation of T cell homeostatic proliferation GO:0046013 8.96 LMO1 IL2

Molecular functions related to T-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.13 TAL1 CREB1 ATF4
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A

Sources for T-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....